On 16 June 2023, representatives from the Drugs for Neglected Diseases Initiative (DNDi) visited C-FREE-CSEA study Drop-in-Centers Samrong run by our partner Raks Thai Foundation, to observe the implementation of the model of care project. The representatives from DNDi included Bernard Pecoul, former Executive Director, Jean-Michel Piedagnel, South-East Asia Director, Aiezat Fadzell, Communications Manager, and Tilak Ramanaidu, Senior Regional Affairs Officer.
DNDi is a non-profit drug research and development organization that develops life-saving medicines to treat neglected diseases and patients. DNDi has been involved with Pharco Pharmaceuticals in the co-development of Ravidasvir, a novel and potent anti-hepatitis C medicine which Dreamlopments now uses in the C-FREE-CSEA project, as part of joint activities to expand access to affordable hepatitis C treatment combinations in Thailand.
From left to right: Dr. Nicolas Durier, Founder & General Director of Dreamlopments, Bernard Pecoul, former Executive Director of DNDi, Jean-Michel Piedagnel, South-East Asia Director of DNDi, Tilak Ramanaidu, Senior Regional Affairs Officer, and Aiezat Fadzell, Communications Manager of DNDi.